Human papillomavirus (HPV) Associated Cancer - Pipeline Insight, 2024

This “Human papillomavirus (HPV) Associated Cancer - Pipeline Insight, 2024,” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Human papillomavirus (HPV) Associated Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Human papillomavirus (HPV) Associated Cancer Understanding

Human papillomavirus (HPV) Associated Cancer: Overview

Human papillomavirus (HPV) infection is linked with several cancers such as cancer cervix, vagina, vulva, head and neck, anal, and penile carcinomas. Although there is a proven association of HPV with these cancers, questions regarding HPV testing, vaccination, and treatment of HPV-related cancers continue to remain unanswered. The present article provides an overview of the HPV-associated cancers.

Among all human cancers, 15% are caused by viral infections. Human papillomavirus (HPV) accounts for approximately 600,000 cases of cancers of the cervix, oropharyngeal cancers, anal cancers, vulvovaginal and penile cancers, as well as a genital wart and recurrent papillomatosis of the lungs worldwide. HPV has an exclusively intra-epithelial infectious cycle and infects both the cutaneous and mucosal squamous epithelium. HPV type 16 and 18 are the most common oncogenic viruses among the HPVs that cause cancer.

The HPV infects squamous epithelial cells, which have the capacity to proliferate, and get access to basal cell during trauma or abrasion. In the basal cells, HPV infection induces the expression of viral genes that helps in the viral replication. The interaction of HPV with the host cells occurs via surface receptors such as heparin sulfate proteoglycans and alpha 6 integrins. The early proteins E1 and E2 are required for the initiation of replication. The protein E2, being the transcriptional repressor of E6 and E7, controls the expression of E6 and E7.

Human papillomavirus (HPV) Associated Cancer - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Human papillomavirus (HPV) Associated Cancer pipeline landscape is provided which includes the disease overview and Human papillomavirus (HPV) Associated Cancer treatment guidelines. The assessment part of the report embraces, in depth Human papillomavirus (HPV) Associated Cancer commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence in Human papillomavirus (HPV) Associated Cancer R&D. The therapies under development are focused on novel approaches to treat/improve in Human papillomavirus (HPV) Associated Cancer.
• In April 2022, SQZ Biotechnologies focused on unlocking the full potential of cell therapies for multiple therapeutic areas, announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for the company’s lead cell therapy candidate, SQZ-PBMC-HPV, for the treatment of HPV16+ advanced or metastatic solid tumors.
• In January 2022, HOOKIPA Pharma announced that the first patient has been dosed with HB-200 in combination with pembrolizumab for the treatment of 1st-line advanced/metastatic Human Papillomavirus 16 Positive (HPV16+) squamous cell head and neck cancers (HNSCC) in a Phase 2 arm of the ongoing Phase 1/2 trial (NCT04180215). In addition, the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to the Company’s novel immunotherapy candidates, single-vector HB-201 and alternating 2-vector HB-202/HB-201, both in combination with pembrolizumab, for the treatment of 1st-line advanced/metastatic HPV16+ HNSCC.

This segment of the Human papillomavirus (HPV) Associated Cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Human papillomavirus (HPV) Associated Cancer Emerging Drugs

STP909: Sirnaomics IncSTP909 comprises siRNA targeting human papillomavirus (HPV) sequences formulated with our PNP delivery platform for intravenous and topical administration. Company developing STP909 as a prophylactic vaccine for prevention of cervical cancer and other disease caused by HPV.

RTX-321: Rubius TherapeuticsRTX-321 is an allogeneic, off-the-shelf aAPC therapy product candidate that is engineered to induce a tumor-specific immune response by expanding antigen-specific T cells. RTX-321 expresses hundreds of thousands of copies of an HPV peptide antigen bound to major histocompatibility complex (MHC) class I proteins, the costimulatory molecule 4-1BBL and the cytokine IL-12 on the cell surface to mimic human T cell-APC interactions.

BVAC-C: Cellid Co LtdBVAC-C uses HPV type 16/18’s carcinogen gene, E6/E7’s recombination gene as antigen to apply on cervical cancer, head and neck cancer, anal cancer, and sex organ cancer caused by HPV infection. CeliVax-based pipeline, BVAC-C, completed phase-I clinical trial to check safety and it is currently undergoing phase-II clinical trial to check effectiveness.

GX-188E: Genexine IncGX-188E is a DNA therapeutic vaccine fused with encoding both E6 and E7 antigens as well as the extracellular domain of Flt3L to target and activate dendritic cells. GX-188E has ability to induce a tumor-specific CD8+ immune response and functional activity to eliminate target cells against high-grade cervical intra-epithelial neoplasms (CIN3, carcinoma in-situ). A phase 1b/2 clinical trial for the cervical cancer patients to evaluate safety, tolerability and efficacy is currently ongoing.

ITI-2000: Immunomic Therapeutics IncITI-2000 provides an UNITE platform address for HPV+ cancers. The oncogenes E6 and E7 in both HPV 16 and HPV 18 strains are well proven to be immunogenic, providing the support to develop this product. ITI-2000, delivered by needle and syringe as a self-amplifying construct, will be indicated for HPV-positive cancers.

Human papillomavirus (HPV) Associated Cancer: Therapeutic Assessment

This segment of the report provides insights about the different Human papillomavirus (HPV) Associated Cancer drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Human papillomavirus (HPV) Associated Cancer

There are approx. 50+ key companies which are developing the therapies for Human papillomavirus (HPV) Associated Cancer. The companies which have their Human papillomavirus (HPV) Associated Cancer drug candidates in the most advanced stage, i.e. Phase III include Advaxis.

Phases

This report covers around 50+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Human papillomavirus (HPV) Associated Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous

Molecule Type

Products have been categorized under various Molecule types such as

• Small molecule
• Gene Therapy
• Cell Therapy
• Immunotherapy

Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Human papillomavirus (HPV) Associated Cancer: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Human papillomavirus (HPV) Associated Cancer therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Human papillomavirus (HPV) Associated Cancer drugs.

Human papillomavirus (HPV) Associated Cancer Report Insights

• Human papillomavirus (HPV) Associated Cancer Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Human papillomavirus (HPV) Associated Cancer Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Human papillomavirus (HPV) Associated Cancer drugs?
• How many Human papillomavirus (HPV) Associated Cancer drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Human papillomavirus (HPV) Associated Cancer?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Human papillomavirus (HPV) Associated Cancer?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Human papillomavirus (HPV) Associated Cancer and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Turnstone Biologics
• Advaxis
• AstraZeneca
• VLP The Vaccines Company SL
• Voltron Therapeutics Inc
• Rubius Therapeutics
• Inovio Pharmaceuticals
• Bristol-Myers Squibb
• Precigen Inc
• Privo Technologies
• ViciniVax BV
• Avalia Immunotherapies
• BlueSky Immunotherapies
• Cellid Co Ltd
• Cue Biopharma
• Cullinan Oncology
• Genexine
• EyeGene
• Hookipa Pharma
• Immunomic Therapeutics
• ISA Pharmaceuticals BV
• SQZ Biotechnologies
• Key Products
• MG1 HPV
• Axalimogene filolisbac
• MEDI 0457
• HPV Cancer Research Project
• MEDI 0457
• RTX 321
• VGX 3100
• Nivolumab
• PRGN-2009
• PRV111
• Vvax001
• AVA1156 (PREC
• delNS HPV 16
• BVAC-C
• CUE-101
• Jade
• GX-188E
• EG-VAC
• HB-200
• ITI-2000
• ISA101b
• SQZ-PBMC-HPV

This product will be delivered within 1-3 business days.